All In Biotech

Drug Trial Radar · NCT00898677

Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)

A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Examine the Safety, Tolerability, and Efficacy of Single Oral Doses of MK0462 5 mg, MK0462 10 mg, and Sumatriptan 100 mg for Acute Treatment of Migraine

Last checked: Nov 19, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,268 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,268

Actual

Start

Sep 1995

Primary completion

May 1996

Study completion Sep 1996

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
May 12, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to compare rizatriptan 10 mg verse sumatriptan 100 mg in the treatment of migraine attacks and duration of relief provided. This study will also provide additional efficacy data on rizatriptan 5 mg and 10 mg for the treatment of migraine.

Conditions

  • Migraine Headache

Interventions

  • rizatriptan benzoateDrug

    single dose administration of 5mg rizatriptan (by Mouth) p.o.

  • rizatriptan benzoateDrug

    single dose administration of 10 mg rizatriptan p.o.

  • Comparator: sumatriptanDrug

    single dose administration of sumatriptan 100 p.o.

  • Comparator: PlaceboDrug

    placebo to rizatriptan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain Relief at 2 Hours After DoseTime frame: 2 hours after dose
  2. Time to Relief Within 2 Hours After DoseTime frame: within 2 hours after dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.